
## Vivian P Bykerk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2978831/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identifying Minimal and Meaningful Change in a <scp>Patientâ€Reported</scp> Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives. Arthritis Care and Research, 2022, 74, 588-597.	3.4	17
2	Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study. Rheumatology, 2022, 61, 606-616.	1.9	9
3	Identification of Distinct Disease Activity Trajectories in Methotrexateâ€Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twentyâ€Four Months. Arthritis Care and Research, 2022, 74, 131-141.	3.4	5
4	Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts. Journal of Rheumatology, 2022, 49, 16-25.	2.0	1
5	Sarilumab monotherapy <i>vs</i> sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatology, 2022, 61, 2596-2602.	1.9	4
6	A Bridge Too Far? Realâ€World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort. ACR Open Rheumatology, 2022, 4, 57-64.	2.1	8
7	Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clinical Rheumatology, 2022, 41, 1619-1622.	2.2	15
8	Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination. Lancet Rheumatology, The, 2022, 4, e85-e87.	3.9	6
9	Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey. Journal of Rheumatology, 2022, 49, 998-1005.	2.0	5
10	Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017â€2021: Results From the Canadian Early Arthritis Cohort. ACR Open Rheumatology, 2022, 4, 566-573.	2.1	2
11	Reply. Arthritis and Rheumatology, 2021, 73, 175-176.	5.6	0
12	Dataâ€Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. Arthritis Care and Research, 2021, 73, 471-480.	3.4	12
13	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. Arthritis and Rheumatology, 2021, 73, 759-768.	5.6	29
14	Reply. Arthritis and Rheumatology, 2021, 73, 357-358.	5.6	0
15	Patients and clinicians define symptom levels and meaningful change for PROMIS pain interference and fatigue in RA using bookmarking. Rheumatology, 2021, 60, 4306-4314.	1.9	13
16	Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Annals of the Rheumatic Diseases, 2021, 80, 1352-1354.	0.9	65
17	Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index. ACR Open Rheumatology, 2021, 3, 501-511.	2.1	4
18	HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. Arthritis Research and Therapy, 2021, 23, 245.	3.5	16

#	Article	IF	CITATIONS
19	1201â€Flares after SARS-Cov-2 vaccination in patients with systemic lupus erythematosus. , 2021, , .		2
20	Evaluating Quality of Care for Rheumatoid Arthritis for the Population of Alberta Using System-level Performance Measures. Journal of Rheumatology, 2021, 48, 482-485.	2.0	9
21	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. Arthritis Care and Research, 2020, 72, 1104-1111.	3.4	10
22	Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change. Journal of Rheumatology, 2020, 47, 333-340.	2.0	5
23	Rheumatoid Arthritis Morning Stiffness Is Associated With Synovial Fibrin and Neutrophils. Arthritis and Rheumatology, 2020, 72, 557-564.	5.6	30
24	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Annals of the Rheumatic Diseases, 2020, 79, 88-93.	0.9	63
25	What Does the Patient Global Health Assessment in Rheumatoid Arthritis Really Tell Us? Contribution of Specific Dimensions of Healthâ€Related Quality of Life. Arthritis Care and Research, 2020, 72, 1571-1578.	3.4	12
26	EP25 Impact of sarilumab on unacceptable pain and inflammation control in moderately-to-severely active rheumatoid arthritis (RA) patients in 3 Phase 3 studies. Rheumatology, 2020, 59, .	1.9	1
27	Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry. ACR Open Rheumatology, 2020, 2, 595-604.	2.1	13
28	The efficacy and safety of targeting GM-CSF in arthritis. Lancet Rheumatology, The, 2020, 2, e648-e650.	3.9	8
29	<p>Using a Discrete-Choice Experiment in a Decision Aid to Nudge Patients Towards Value-Concordant Treatment Choices in Rheumatoid Arthritis: A Proof-of-Concept Study</p> . Patient Preference and Adherence, 2020, Volume 14, 829-838.	1.8	12
30	A Call to Systematically Monitor for Adverse Events in Users of Low-Dose Methotrexate Therapy. Annals of Internal Medicine, 2020, 172, 425.	3.9	3
31	Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: AÂSystematic Review. Arthritis Care and Research, 2019, 71, 620-628.	3.4	12
32	PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis. Journal of Patient-Reported Outcomes, 2019, 3, 14.	1.9	33
33	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open, 2019, 5, e000942.	3.8	45
34	Joint Estimation of Remission and Response for Methotrexateâ€Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Metaâ€Analysis. ACR Open Rheumatology, 2019, 1, 471-479.	2.1	5
35	Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care. BMC Health Services Research, 2019, 19, 572.	2.2	7
36	Patient-Reported Outcomes Measurement Information System Versus Legacy Instruments. Rheumatic Disease Clinics of North America, 2019, 45, 211-229.	1.9	11

#	Article	IF	CITATIONS
37	HBEGF <sup>+</sup> macrophages in rheumatoid arthritis induce fibroblast invasiveness. Science Translational Medicine, 2019, 11, .	12.4	143
38	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open, 2019, 5, e000840.	3.8	8
39	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nature Immunology, 2019, 20, 928-942.	14.5	760
40	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. Clinical Rheumatology, 2019, 38, 2411-2421.	2.2	4
41	Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Patients With Rheumatoid Arthritis in Clinical Remission. Arthritis and Rheumatology, 2019, 71, 1034-1041.	5.6	19
42	Low-dose Glucocorticoid Use Does Not Reduce Biologic Use in Early RA, Nor Do Biologics Reduce the Need for Glucocorticoids. Journal of Rheumatology, 2019, 46, 331-332.	2.0	1
43	Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. Journal of Rheumatology, 2019, 46, 1168-1172.	2.0	8
44	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. Journal of Rheumatology, 2019, 46, 1406-1408.	2.0	6
45	THU0153â€PATTERNS OF SUSTAINED REMISSION AND SUBSEQUENT DMARD TAPERING IN EARLY RHEUMATC ARTHRITIS: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT. , 2019, , .	ID	Ο
46	OP0089â€METABOLIC SYNDROME IS COMMON AROUND THE TIME OF EARLY RHEUMATOID ARTHRITIS DIAGNOSIS AND ASSOCIATIONS VARY BY SEX AND MENOPAUSAL STATUS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT. , 2019, , .		0
47	AB1079â€CHECKPOINT INHIBITOR-ASSOCIATED ARTHRITIS: PHENOTYPES AND CYTOKINE ASSOCIATIONS. , 20	)19,,	0
48	FRI0065â€PATIENT-REPORTED PALINDROMIC SYMPTOMS IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM CANADIAN EARLY ARTHRITIS COHORT. , 2019, , .	THE	0
49	OP0315â€ACHIEVING A LOW DISEASE STATE WITHIN FIRST 3 MONTHS IN EARLY RHEUMATOID ARTHRITIS RESULTS IN LOWER FATIGUE OVER 5 YEARS. , 2019, , .		2
50	AB1304â€THE RHEUMATOID ARTHRITIS FLARE QUESTIONNAIRE (RA-FQ) IS AN EASY TO ADMINISTER PATIENT-REPORTED OUTCOME MEASURE THAT TRACKS WELL WITH THE CLINICAL DISEASE ACTIVITY INDEX (CDAI) OVER TIME IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (ERA) IN 2 DIFFERENT HEALTH SETTINGS. , 2019, , .		0
51	OP0269â€HPR PATTERNS OF FATIGUE AND PREDICTORS OF SIGNIFICANT IMPROVEMENT IN THE 1ST YEAR OF RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH). , 2019, , .	RA:	Ο
52	LB0008â€THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICALEFFICACY OF ABATACEPT AND ADALIMUN IN SEROPOSITIVE BIOLOGIC-NAÃ℃E PATIENTSWITH EARLY, MODERATE-TO-SEVERE RA: DATA FROM A HEAD-TO-HEAD SINGLE-BLINDEDTRIAL. , 2019, , .	IAB	3
53	A quarter of patients time their early rheumatoid arthritis onset differently than physicians. RMD Open, 2019, 5, e000931.	3.8	1
54	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36

#	Article	IF	CITATIONS
55	Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and <scp>RNA</scp> Sequencing Data. Arthritis and Rheumatology, 2018, 70, 690-701.	5.6	157
56	Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation. Nature Communications, 2018, 9, 791.	12.8	284
57	Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nature Communications, 2018, 9, 789.	12.8	368
58	Moving towards IMPROVED drug-free remission. Nature Reviews Rheumatology, 2018, 14, 191-192.	8.0	0
59	Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors. Journal of Rheumatology, 2018, 45, 604-611.	2.0	41
60	Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study. Arthritis Care and Research, 2018, 70, 1185-1191.	3.4	38
61	Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis. Arthritis Care and Research, 2018, 70, 1245-1250.	3.4	15
62	Mixed-effects association of single cells identifies an expanded effector CD4 <sup>+</sup> T cell subset in rheumatoid arthritis. Science Translational Medicine, 2018, 10, .	12.4	119
63	On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Rheumatology International, 2018, 38, 2225-2231.	3.0	4
64	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. Arthritis Research and Therapy, 2018, 20, 139.	3.5	93
65	Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature, 2017, 542, 110-114.	27.8	767
66	The effect of rheumatoid arthritis–associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. Rheumatology, 2017, 56, kew474.	1.9	18
67	Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE. Annals of the Rheumatic Diseases, 2017, 76, 740-747.	0.9	73
68	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
69	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis and Rheumatology, 2017, 69, 2187-2192.	5.6	35
70	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. Journal of Rheumatology, 2017, 44, 1536-1543.	2.0	25
71	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 1937-1948.	5.6	32
72	Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort. Arthritis Care and Research, 2017, 69, 737-741.	3.4	3

#	Article	IF	CITATIONS
73	A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). PLoS ONE, 2017, 12, e0189840.	2.5	26
74	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and SjA¶gren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	5.6	114
75	Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology, 2016, 55, kev364.	1.9	41
76	Reduction in Serum Uric Acid may be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2016, 9, CMAMD.S38092.	1.2	15
77	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open, 2016, 2, e000225.	3.8	54
78	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1501-1505.	0.9	17
79	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. Clinical Immunology, 2016, 168, 25-29.	3.2	68
80	Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. Rheumatology, 2016, 55, 1959-1968.	1.9	59
81	Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. Rheumatology, 2016, 55, 1751-1762.	1.9	29
82	Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. Journal of Rheumatology, 2016, 43, 1997-2009.	2.0	78
83	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1003-1008.	0.9	56
84	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases, 2016, 75, 16-22.	0.9	275
85	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.9	1,114
86	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. Journal of Rheumatology, 2015, 42, 2185-2189.	2.0	40
87	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). PLoS ONE, 2015, 10, e0135327.	2.5	32
88	Does Socioeconomic Status Affect Outcomes in Early Inflammatory Arthritis? Data from a Canadian Multisite Suspected Rheumatoid Arthritis Inception Cohort. Journal of Rheumatology, 2015, 42, 46-54.	2.0	23
89	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24â€months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases, 2015, 74, 19-26.	0.9	201
90	Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clinical Rheumatology, 2015, 34, 563-571.	2.2	36

#	Article	IF	CITATIONS
91	14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 1587-1594.	2.0	28
92	Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clinical and Experimental Rheumatology, 2015, 33, 272-8.	0.8	30
93	Radiographic Progression in Rheumatoid Arthritis: Does It Still Happen and Does It Matter?. Journal of Rheumatology, 2014, 41, 2337-2339.	2.0	1
94	Prognosis of Seronegative Patients in a Large Prospective Cohort of Patients with Early Inflammatory Arthritis. Journal of Rheumatology, 2014, 41, 2361-2369.	2.0	71
95	Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. Rheumatology, 2014, 53, 1075-1086.	1.9	37
96	Earlier Time to Remission Predicts Sustained Clinical Remission in Early Rheumatoid Arthritis — Results from the Canadian Early Arthritis Cohort (CATCH). Journal of Rheumatology, 2014, 41, 2161-2166.	2.0	44
97	Flares in Rheumatoid Arthritis: Frequency and Management. A Report from the BRASS Registry. Journal of Rheumatology, 2014, 41, 227-234.	2.0	52
98	Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 2104-2113.	2.0	72
99	Detecting the Earliest Signs of Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2014, 40, 669-683.	1.9	9
100	Adding a "GRADE―to the quality appraisal of rheumatoid arthritis guidelines identifies limitations beyond AGREE-II. Journal of Clinical Epidemiology, 2014, 67, 1274-1285.	5.0	16
101	Preclinical Rheumatic Disease. Rheumatic Disease Clinics of North America, 2014, 40, xv-xviii.	1.9	2
102	Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. Journal of Rheumatology, 2014, 41, 799-809.	2.0	65
103	Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. Rheumatology International, 2013, 33, 1105-1120.	3.0	23
104	A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Annals of the Rheumatic Diseases, 2013, 72, 13-22.	0.9	95
105	Preface. Best Practice and Research in Clinical Rheumatology, 2013, 27, 449.	3.3	0
106	Early rheumatoid arthritis: The performance of the 2010 ACR/EULAR criteria for diagnosing RA. Best Practice and Research in Clinical Rheumatology, 2013, 27, 451-466.	3.3	43
107	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102
108	Treatment strategies for early rheumatoid arthritis. Current Opinion in Rheumatology, 2013, 25, 375-383.	4.3	6

#	Article	IF	CITATIONS
109	Determining Best Practices in Early Rheumatoid Arthritis by Comparing Differences in Treatment at Sites in the Canadian Early Arthritis Cohort. Journal of Rheumatology, 2013, 40, 1823-1830.	2.0	26
110	Validation of a Self-administered Inflammatory Arthritis Detection Tool for Rheumatology Triage. Journal of Rheumatology, 2013, 40, 417-424.	2.0	12
111	Achieving remission in clinical practice: lessons from clinical trial data. Clinical and Experimental Rheumatology, 2013, 31, 621-32.	0.8	13
112	The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity. Journal of Rheumatology, 2012, 39, 2071-2080.	2.0	46
113	Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety. Journal of Rheumatology, 2012, 39, 1583-1602.	2.0	122
114	Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. Journal of Rheumatology, 2012, 39, 1559-1582.	2.0	250
115	The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology, 2012, 51, vi16-vi20.	1.9	43
116	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Annals of the Rheumatic Diseases, 2012, 71, 1855-1860.	0.9	131
117	Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology, 2012, 51, 1416-1425.	1.9	71
118	Remission in Early Rheumatoid Arthritis — A Comparison of New ACR/EULAR Remission Criteria to Established Criteria. Journal of Rheumatology, 2012, 39, 1155-1158.	2.0	32
119	The new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic?. Rheumatology, 2012, 51, vi10-vi15.	1.9	15
120	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Annals of the Rheumatic Diseases, 2012, 71, 1950-1954.	0.9	91
121	Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Annals of the Rheumatic Diseases, 2012, 71, 681-686.	0.9	150
122	Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Research and Therapy, 2012, 14, R68.	3.5	83
123	2011 remission criteria are a new benchmark for RA therapy. Nature Reviews Rheumatology, 2011, 7, 317-318.	8.0	8
124	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. Journal of rheumatology Supplement, The, 2011, 87, 54-58.	2.2	11
125	Strategies to prevent rheumatoid arthritis in high-risk patients. Current Opinion in Rheumatology, 2011, 23, 179-184.	4.3	10
126	Development of a self-administered early inflammatory arthritis detection tool. BMC Musculoskeletal Disorders, 2010, 11, 50.	1.9	31

#	Article	IF	CITATIONS
127	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis and Rheumatism, 2010, 62, 2582-2591.	6.7	246
128	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781
129	Delay in receiving rheumatology care leads to longâ€ŧerm harm. Arthritis and Rheumatism, 2010, 62, 3519-3521.	6.7	54
130	Canadian Recommendations for Use of Methotrexate in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 1422-1430.	2.0	34
131	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. Annals of the Rheumatic Diseases, 2010, 69, 1589-1595.	0.9	152
132	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	0.9	2,994
133	Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of Fibromyalgia. Arthritis and Rheumatism, 1994, 37, 32-40.	6.7	325
134	Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 1993, 36, 795-803.	6.7	152
135	087 On Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis. Rheumatology, 0, , .	1.9	1
136	Modification of immunomodulatory medications by rheumatology patients during the peak of the COVID-19 pandemic in New York City. Clinical Rheumatology, 0, , .	2.2	0